Chemed reiterates $22–$22.30 EPS guidance for 2025 as Roto-Rooter margins stabilize and VITAS targets Medicare Cap resolution (NYSE:CHE)
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]
Group 1 - The article does not provide any relevant content regarding company or industry insights [1]